{"pmid":32266987,"title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).","text":["Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).","OBJECTIVES: To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). DESIGN, SETTING: Observational study in the two COVID-19-designated hospitals in Wuhu, Anhui province, China, 24 January - 24 February 2020. PARTICIPANTS: Thirty-one patients infected with the severe acute respiratory coronavirus 2 (SARS-CoV-2) treated at the two designated hospitals. MAIN OUTCOME MEASURES: Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy). RESULTS: Eleven of 31 patients with COVID-19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [HR], 1.26; 95% CI, 0.58-2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33-1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40-1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% CI, 6.2-15.1 days). CONCLUSIONS: Corticosteroids are widely used when treating patients with COVID-19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing HBV infection may delay SARS-CoV-2 clearance, and this association should be further investigated.","Med J Aust","Zha, Lei","Li, Shirong","Pan, Lingling","Tefsen, Boris","Li, Yeshan","French, Neil","Chen, Liyun","Yang, Gang","Villanueva, Elmer V","32266987"],"abstract":["OBJECTIVES: To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). DESIGN, SETTING: Observational study in the two COVID-19-designated hospitals in Wuhu, Anhui province, China, 24 January - 24 February 2020. PARTICIPANTS: Thirty-one patients infected with the severe acute respiratory coronavirus 2 (SARS-CoV-2) treated at the two designated hospitals. MAIN OUTCOME MEASURES: Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy). RESULTS: Eleven of 31 patients with COVID-19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [HR], 1.26; 95% CI, 0.58-2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33-1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40-1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% CI, 6.2-15.1 days). CONCLUSIONS: Corticosteroids are widely used when treating patients with COVID-19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing HBV infection may delay SARS-CoV-2 clearance, and this association should be further investigated."],"journal":"Med J Aust","authors":["Zha, Lei","Li, Shirong","Pan, Lingling","Tefsen, Boris","Li, Yeshan","French, Neil","Chen, Liyun","Yang, Gang","Villanueva, Elmer V"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266987","week":"202015|Apr 06 - Apr 12","doi":"10.5694/mja2.50577","keywords":["Corticosteroids","Epidemics","Pneumonia, viral"],"source":"PubMed","locations":["China","Wuhu","Anhui"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663609715752435712,"score":7.9164424,"similar":[{"pmid":32271376,"title":"Factors associated with prolonged viral RNA shedding in patients with COVID-19.","text":["Factors associated with prolonged viral RNA shedding in patients with COVID-19.","BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) is becoming a public health emergency. Data are limited on the duration and host factors related to viral shedding. METHODS: In this retrospective study, risk factors associated with severe acute respiratory coronavirus 2 (SARS-CoV-2) RNA shedding were evaluated in a cohort of 113 symptomatic patients from two hospitals outside Wuhan. RESULTS: The median duration of SARS-CoV-2 RNA detection was 17 days (Interquartile Range [IQR], 13-22 days) as measured from illness onset. When comparing patients with early (<15 days) and late viral RNA clearance (>/=15 days after illness onset), prolonged SARS-CoV-2 RNA shedding was associated with male sex (p=0.009), old age (p=0.033), concomitated with hypertension (p=0.009), delayed admission to hospital after illness onset (p=0.001), severe illness at admission (p=0.049), invasive mechanical ventilation (p=0.006), and corticosteroid treatment (p=0.025). Patients with longer SARS-CoV-2 RNA shedding duration had slower recovery of body temperature (p<0.001) and focal absorption on radiograph images (p<0.001) than patients with early SARS-CoV-2 RNA clearance. Male sex (odds ratio [OR], 3.24 [95% CI, 1.31-8.02]), delayed hospital admission (OR, 1.30 [95% CI, 1.10-1.54]), and invasive mechanical ventilation (OR, 9.88 [95% CI, 1.11-88.02]) were independent risk factors for prolonged SARS-CoV-2 RNA shedding. CONCLUSIONS: Male sex, delayed admission to hospital after illness onset, and invasive mechanical ventilation were associated with prolonged SARS-CoV-2 RNA shedding. Hospital admission and general treatments should be started as soon as possible in symptomatic COVID-19 patients, especially male patients.","Clin Infect Dis","Xu, Kaijin","Chen, Yanfei","Yuan, Jing","Yi, Ping","Ding, Cheng","Wu, Wenrui","Li, Yongtao","Ni, Qin","Zou, Rongrong","Li, Xiaohe","Xu, Min","Zhang, Ying","Zhao, Hong","Zhang, Xuan","Yu, Liang","Su, Junwei","Lang, Guanjing","Liu, Jun","Wu, Xiaoxin","Guo, Yongzheng","Tao, Jingjing","Shi, Ding","Yu, Ling","Cao, Qing","Ruan, Bing","Liu, Lei","Wang, Zhaoqin","Xu, Yan","Liu, Yingxia","Sheng, Jifang","Li, Lanjuan","32271376"],"abstract":["BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) is becoming a public health emergency. Data are limited on the duration and host factors related to viral shedding. METHODS: In this retrospective study, risk factors associated with severe acute respiratory coronavirus 2 (SARS-CoV-2) RNA shedding were evaluated in a cohort of 113 symptomatic patients from two hospitals outside Wuhan. RESULTS: The median duration of SARS-CoV-2 RNA detection was 17 days (Interquartile Range [IQR], 13-22 days) as measured from illness onset. When comparing patients with early (<15 days) and late viral RNA clearance (>/=15 days after illness onset), prolonged SARS-CoV-2 RNA shedding was associated with male sex (p=0.009), old age (p=0.033), concomitated with hypertension (p=0.009), delayed admission to hospital after illness onset (p=0.001), severe illness at admission (p=0.049), invasive mechanical ventilation (p=0.006), and corticosteroid treatment (p=0.025). Patients with longer SARS-CoV-2 RNA shedding duration had slower recovery of body temperature (p<0.001) and focal absorption on radiograph images (p<0.001) than patients with early SARS-CoV-2 RNA clearance. Male sex (odds ratio [OR], 3.24 [95% CI, 1.31-8.02]), delayed hospital admission (OR, 1.30 [95% CI, 1.10-1.54]), and invasive mechanical ventilation (OR, 9.88 [95% CI, 1.11-88.02]) were independent risk factors for prolonged SARS-CoV-2 RNA shedding. CONCLUSIONS: Male sex, delayed admission to hospital after illness onset, and invasive mechanical ventilation were associated with prolonged SARS-CoV-2 RNA shedding. Hospital admission and general treatments should be started as soon as possible in symptomatic COVID-19 patients, especially male patients."],"journal":"Clin Infect Dis","authors":["Xu, Kaijin","Chen, Yanfei","Yuan, Jing","Yi, Ping","Ding, Cheng","Wu, Wenrui","Li, Yongtao","Ni, Qin","Zou, Rongrong","Li, Xiaohe","Xu, Min","Zhang, Ying","Zhao, Hong","Zhang, Xuan","Yu, Liang","Su, Junwei","Lang, Guanjing","Liu, Jun","Wu, Xiaoxin","Guo, Yongzheng","Tao, Jingjing","Shi, Ding","Yu, Ling","Cao, Qing","Ruan, Bing","Liu, Lei","Wang, Zhaoqin","Xu, Yan","Liu, Yingxia","Sheng, Jifang","Li, Lanjuan"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271376","week":"202015|Apr 06 - Apr 12","doi":"10.1093/cid/ciaa351","keywords":["COVID-19","Coronavirus","SARS-COV-2","risk factors","viral shedding"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1663620083074727937,"score":364.13644},{"pmid":32167524,"pmcid":"PMC7070509","title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.","text":["Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.","Importance: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated. Objective: To describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died. Design, Setting, and Participants: Retrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. The final date of follow-up was February 13, 2020. Exposures: Confirmed COVID-19 pneumonia. Main Outcomes and Measures: The development of ARDS and death. Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed. Results: Of 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). In bivariate Cox regression analysis, risk factors associated with the development of ARDS and progression from ARDS to death included older age (hazard ratio [HR], 3.26; 95% CI 2.08-5.11; and HR, 6.17; 95% CI, 3.26-11.67, respectively), neutrophilia (HR, 1.14; 95% CI, 1.09-1.19; and HR, 1.08; 95% CI, 1.01-1.17, respectively), and organ and coagulation dysfunction (eg, higher lactate dehydrogenase [HR, 1.61; 95% CI, 1.44-1.79; and HR, 1.30; 95% CI, 1.11-1.52, respectively] and D-dimer [HR, 1.03; 95% CI, 1.01-1.04; and HR, 1.02; 95% CI, 1.01-1.04, respectively]). High fever (>/=39 degrees C) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72). Conclusions and Relevance: Older age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS.","JAMA Intern Med","Wu, Chaomin","Chen, Xiaoyan","Cai, Yanping","Xia, Jia'an","Zhou, Xing","Xu, Sha","Huang, Hanping","Zhang, Li","Zhou, Xia","Du, Chunling","Zhang, Yuye","Song, Juan","Wang, Sijiao","Chao, Yencheng","Yang, Zeyong","Xu, Jie","Zhou, Xin","Chen, Dechang","Xiong, Weining","Xu, Lei","Zhou, Feng","Jiang, Jinjun","Bai, Chunxue","Zheng, Junhua","Song, Yuanlin","32167524"],"abstract":["Importance: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated. Objective: To describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died. Design, Setting, and Participants: Retrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. The final date of follow-up was February 13, 2020. Exposures: Confirmed COVID-19 pneumonia. Main Outcomes and Measures: The development of ARDS and death. Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed. Results: Of 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). In bivariate Cox regression analysis, risk factors associated with the development of ARDS and progression from ARDS to death included older age (hazard ratio [HR], 3.26; 95% CI 2.08-5.11; and HR, 6.17; 95% CI, 3.26-11.67, respectively), neutrophilia (HR, 1.14; 95% CI, 1.09-1.19; and HR, 1.08; 95% CI, 1.01-1.17, respectively), and organ and coagulation dysfunction (eg, higher lactate dehydrogenase [HR, 1.61; 95% CI, 1.44-1.79; and HR, 1.30; 95% CI, 1.11-1.52, respectively] and D-dimer [HR, 1.03; 95% CI, 1.01-1.04; and HR, 1.02; 95% CI, 1.01-1.04, respectively]). High fever (>/=39 degrees C) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72). Conclusions and Relevance: Older age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS."],"journal":"JAMA Intern Med","authors":["Wu, Chaomin","Chen, Xiaoyan","Cai, Yanping","Xia, Jia'an","Zhou, Xing","Xu, Sha","Huang, Hanping","Zhang, Li","Zhou, Xia","Du, Chunling","Zhang, Yuye","Song, Juan","Wang, Sijiao","Chao, Yencheng","Yang, Zeyong","Xu, Jie","Zhou, Xin","Chen, Dechang","Xiong, Weining","Xu, Lei","Zhou, Feng","Jiang, Jinjun","Bai, Chunxue","Zheng, Junhua","Song, Yuanlin"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167524","week":"202011|Mar 09 - Mar 15","doi":"10.1001/jamainternmed.2020.0994","source":"PubMed","locations":["ARDS","Wuhan","China","Pneumonia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"e_drugs":["Methylprednisolone"],"_version_":1663352133991268355,"score":315.45898},{"pmid":32274772,"title":"Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic.","text":["Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic.","The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations. . Corticosteroid use is an important part of prematurity treatment because it provides benefit to the fetus.. . Corticosteroid use may be related with increased morbidity and mortality in novel coronavirus disease 2019 (COVID-19).. . Therefore, during the COVID-19 pandemic, an alteration in current corticosteroid practices is necessary to uniquely weigh the maternal risks and fetal benefits..","Am J Perinatol","McIntosh, Jennifer Jury","32274772"],"abstract":["The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations. . Corticosteroid use is an important part of prematurity treatment because it provides benefit to the fetus.. . Corticosteroid use may be related with increased morbidity and mortality in novel coronavirus disease 2019 (COVID-19).. . Therefore, during the COVID-19 pandemic, an alteration in current corticosteroid practices is necessary to uniquely weigh the maternal risks and fetal benefits.."],"journal":"Am J Perinatol","authors":["McIntosh, Jennifer Jury"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274772","week":"202015|Apr 06 - Apr 12","doi":"10.1055/s-0040-1709684","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663712077860044800,"score":298.2038},{"pmid":32171869,"pmcid":"PMC7102530","title":"Clinical progression of patients with COVID-19 in Shanghai, China.","text":["Clinical progression of patients with COVID-19 in Shanghai, China.","BACKGROUND: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19. METHODS: In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020. RESULTS: Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2-7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12-20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8-11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10-12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR]=1.06) and CD4 T cell count (OR=0.55 per 100 cells/ul increase) were independently associated with ICU admission. CONCLUSIONS: The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19.","J Infect","Chen, Jun","Qi, Tangkai","Liu, Li","Ling, Yun","Qian, Zhiping","Li, Tao","Li, Feng","Xu, Qingnian","Zhang, Yuyi","Xu, Shuibao","Song, Zhigang","Zeng, Yigang","Shen, Yinzhong","Shi, Yuxin","Zhu, Tongyu","Lu, Hongzhou","32171869"],"abstract":["BACKGROUND: Studies on the 2019 novel coronavirus disease (COVID-19) have generally been limited to the description of the epidemiology and initial clinical characteristics. We investigated the temporal progression in patients with COVID-19. METHODS: In this retrospective, single-center study, we included confirmed cases of COVID-19 from Jan 20 to Feb 6, 2020 in Shanghai. Final date of follow-up was February 25, 2020. RESULTS: Of the 249 patients enrolled, the median age was 51 years old, and 126 (50.6%) were male. The duration from onset of symptoms to hospitalization was 4(2-7) days in symptomatic patients. Fever was occurred in 235(94.3%) patients. A total of 215 (86.3%) patients had been discharged after 16(12-20) days hospitalization. The estimated median duration of fever in all the patients with fever was 10 days (95 confidential intervals [CIs]: 8-11 days) after onset of symptoms. Patients who were transferred to intensive care units (ICU) had significantly longer duration of fever as compared to those not in ICU (31 days v.s. 9 days after onset of symptoms, respectively, P <0.0001). Radiological aggravation of initial image was observed in 163 (65.7%) patients on day 7 after onset of symptoms. 154(94.5%) of these patients showed radiological improvement on day 14. The median duration to negative reverse-transcriptase PCR tests of upper respiratory tract samples was 11 days (95 CIs: 10-12 days). Viral clearance was more likely to be delayed in patients in ICU than those not in ICU (P <0.0001). In multivariate logistical analysis, age (Odds ratio [OR]=1.06) and CD4 T cell count (OR=0.55 per 100 cells/ul increase) were independently associated with ICU admission. CONCLUSIONS: The majority of COVID-19 cases are mild. The clinical progression pattern suggests that early control of viral replication and application of host-directed therapy in later stage is essential to improve the prognosis of CVOID-19."],"journal":"J Infect","authors":["Chen, Jun","Qi, Tangkai","Liu, Li","Ling, Yun","Qian, Zhiping","Li, Tao","Li, Feng","Xu, Qingnian","Zhang, Yuyi","Xu, Shuibao","Song, Zhigang","Zeng, Yigang","Shen, Yinzhong","Shi, Yuxin","Zhu, Tongyu","Lu, Hongzhou"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32171869","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.jinf.2020.03.004","keywords":["COVID-19","Clinical characteristics","Clinical progression","SARS-CoV-2","Viral clearance"],"source":"PubMed","locations":["Shanghai","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352133939888128,"score":273.62076},{"pmid":32227274,"title":"The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.","text":["The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.","OBJECTIVE: This study aims to evaluate the correlation between viral clearance and blood biochemical index of 94 discharged patients with COVID-19 infection in Shenzhen Third People's Hospital, enrolled from Jan 5 to Feb 13, 2020. METHODS: The clinical and laboratory findings were extracted from the electronic medical records of the patients. The data were analysed and reviewed by a trained team of physicians. Information on clinical signs and symptoms, medical treatment, virus clearance, and laboratory parameters including interleukin 6 (IL-6) and C-reactive protein were collected. RESULTS: COVID-19 mRNA clearance ratio was identified significantly correlated with the decline of serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels. Furthermore, COVID-19 mRNA clearance time was positively correlated with the length of hospital stay in patients treated with either IFN-alpha + lopinavir/ritonavir or IFN-alpha + lopinavir/ritonavir + ribavirin. CONCLUSIONS: Therapeutic regimens of IFN-alpha + lopinavir/ritonavir and IFN-alpha + lopinavir/ritonavir + ribavirin might be beneficial for treatment of COVID-19. Serum LDH or CK decline may predict a favorable response to treatment of COVID-19 infection.","Inflamm Res","Yuan, Jing","Zou, Rougrong","Zeng, Lijiao","Kou, Shanglong","Lan, Jianfeng","Li, Xiaohe","Liang, Yanhua","Ding, Xiaoyan","Tan, Guoyu","Tang, Shenghong","Liu, Lei","Liu, Yingxia","Pan, Yanchao","Wang, Zhaoqin","32227274"],"abstract":["OBJECTIVE: This study aims to evaluate the correlation between viral clearance and blood biochemical index of 94 discharged patients with COVID-19 infection in Shenzhen Third People's Hospital, enrolled from Jan 5 to Feb 13, 2020. METHODS: The clinical and laboratory findings were extracted from the electronic medical records of the patients. The data were analysed and reviewed by a trained team of physicians. Information on clinical signs and symptoms, medical treatment, virus clearance, and laboratory parameters including interleukin 6 (IL-6) and C-reactive protein were collected. RESULTS: COVID-19 mRNA clearance ratio was identified significantly correlated with the decline of serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels. Furthermore, COVID-19 mRNA clearance time was positively correlated with the length of hospital stay in patients treated with either IFN-alpha + lopinavir/ritonavir or IFN-alpha + lopinavir/ritonavir + ribavirin. CONCLUSIONS: Therapeutic regimens of IFN-alpha + lopinavir/ritonavir and IFN-alpha + lopinavir/ritonavir + ribavirin might be beneficial for treatment of COVID-19. Serum LDH or CK decline may predict a favorable response to treatment of COVID-19 infection."],"journal":"Inflamm Res","authors":["Yuan, Jing","Zou, Rougrong","Zeng, Lijiao","Kou, Shanglong","Lan, Jianfeng","Li, Xiaohe","Liang, Yanhua","Ding, Xiaoyan","Tan, Guoyu","Tang, Shenghong","Liu, Lei","Liu, Yingxia","Pan, Yanchao","Wang, Zhaoqin"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227274","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s00011-020-01342-0","keywords":["CK","COVID-19","Clearance ratio","LDH"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Ribavirin","Ritonavir","Lopinavir"],"_version_":1663352135313522690,"score":271.02234}]}